Compare Incyte Corporation (INCY) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Macy's Inc — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.85B), while Macy's Inc trades at $22.79 (market cap $5.95B). The key difference: Incyte Corporation is far larger — about 3.8× Macy's Inc's market cap, and Macy's Inc pays a 3.36% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Macy's Inc for 58 Days on average.
| INCY | M | |
|---|---|---|
Market Cap | $22.85B | $5.95B |
Volume | 1,927,029 | 6,030,644 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $26.21 |
52-Week Low | $83.80 | $16.51 |
Typical Hold Time | 33 Days | 58 Days |
Enterprise Value | $18.35B | $9.75B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Macy's stock trades at $22.79, up 1.47% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals, with Q2 2026 EPS beating estimates and a raised 2026 outlook. Valuation remains attractive with a P/E of 8.35 and P/S of 0.27, while cash flow trends have strengthened, with net cash flow turning positive in 2024 and 2025. Recent news highlights progress in the 'Bold New Chapter' strategy, focusing on digital and omnichannel growth.
The outlook for Macy's is cautiously optimistic, supported by cheap valuations and strategic initiatives, but risks include competitive pressures and uneven earnings growth. Analyst consensus is mixed with a $24.25 price target, indicating modest upside potential. Key investment opportunities lie in dividend yield and turnaround execution, while risks involve margin pressure and macroeconomic headwinds affecting retail demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
